Pharmacokinetic and pharmacodynamic interactions of mefloquine and quinine

International Journal of Clinical Pharmacology Research

Volumn 19, Issue 3, 1999, Pages 73-82

  Na Bangchang, K ^a,c   Tan Ariya, P ^b   Thanavibul, A ^a   Riengchainam, S ^b   Shrestha, S B ^a   Karbwang, J ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Mahidol University   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; MEFLOQUINE; QUININE;

ADULT; ADVERSE DRUG REACTION; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ELECTROCARDIOGRAM; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PLASMODIUM FALCIPARUM; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANIMALS; ANTIMALARIALS; CROSS-OVER STUDIES; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; MALE; MEFLOQUINE; MIDDLE AGED; PLASMODIUM FALCIPARUM; QUININE;

EID: 0033505842     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wernsdorfer W.H. Epidemiology of drug resistance in malaria. Acta Trop., 56, 143, 1994.
2. Karbwang J., Harinasuta T. Distribution of drug resistance. In: Karbwang J., Harinasuta T. (Eds.). "Chemotherapy of Malaria in Southeast Asia". Roumtassana Co., Bangkok, 1992, pp. 48-72.
3. Congpuong K., Sinchaisinthop J., Tippawangkosol P., et al. Incidence of antimalarial pretreatment and drug sensitivity in vitro in multidrug-resistant Plasmodium falciparum infection in Thailand. Trans. R. Soc. Trop. Med. Hyg., 92, 84, 1998.
4. Karbwang J., Back D.J., Bunnag D., Breckenridge A.M. A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur. J. Clin. Pharmacol., 35, 677, 1988.
5. Supanaranond W., Davis T.M.E., Pukritayakamee S., Nagachinta B., White N.J. Abnormal circulatory control in falciparum malaria: The effects of antimalarial drugs. Eur. J. Clin. Pharmacol., 44, 325, 1993.
6. Ekue J.M.K., Ulrich A.M., Rwawogo-Atenyi J., Sheth U.K. A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull. W.H.O., 61, 713, 1983.
7. Orme M.L.E. Side effects of quinine and derivatives. Acta Leid., 55, 77, 1987.
8. Karbwang J., Davis T.M.E., Looareesuwan S., Molunto P., Bunnag D., White N.J. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine in healthy Thai males. Br. J. Clin. Pharmacol., 35, 265, 1993.
9. Ter-Kuile F., Dolan G., Nosten F., et al. Halofantrine versus mefloquine in treatment of multidrug resistant P. falciparum. Lancet, 341, 1044, 1993.
10. World Health Organization, Advance in malaria chemotherapy. W.H.O. Tech. Rep., 711, 1984.
11. Karbwang J., Molunto P., Na-Bangchang K., Bunnag D. Determination of mefloquine in biological fluids by high performance liquid chromatography. Southeast Asian J. Trop. Med. Public Health, 20, 61, 1989.
12. Karbwang J., Na-Bangchang K., Molunto P., Bunnag D. Determination of quinine and quinidine in biological fluids by high performance liquid chromatography. Southeast Asian J. Trop. Med. Public Health, 20, 65, 1989.
13. Gibaldi M. "Biopharmaceutics and Clinical Pharmacokinetics". 4th Edition. Lea and Febriger, Philadelphia, 1991, pp. 14-23.
14. Thaithong S., Beale G.H., Chutmongkonkul M. Susceptibility of Plasmodium falciparum to five drugs: An in vitro susceptibility study of isolates mainly from Thailand. Trans. R. Soc. Trop. Med. Hyg., 77, 228, 1989.
15. Rieckman K.H., Campel G.H., Sax L.J., Mrema J.E. Drug sensitivity in Plamodium falciparum: An in vitro micro-technique. Lancet, 1, 22, 1979.
16. Trager W., Jensen J.B. Human malaria parasites in continuous culture. Science, 193, 673, 1976.
17. Karbwang J., Bunnag D., Breckenridge A.M., Back D.J. The pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria. Eur. J. Clin. Pharmacol., 32, 173, 1987.
18. Wanwimonruk S., Kaewvichit S., Tanthayaphinant O., Suwannarach C., Ranratnachai A. Lack of effect of oral contraceptive use on the pharmacokinetics of quinine. Br. J. Clin. Pharmacol., 31, 179, 1991.
19. Hakanson A., Lingren A.L., Bjorkman A. Comparison of the activity in vitro of mefloquine and two metabolites against Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg., 84, 503, 1990.
20. Nosten F., Ter-Kuile F.O., Luxemberger C., et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet, 341, 1054, 1993.
21. Supanaranond W., Suputtamongkol Y., Davis T.M.E., et al. Lack of significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Trans. R. Soc. Trop. Med. Hyg., 91, 694, 1997.
22. Hashiba K., Moss A.J., Schwartz P.J. QT prolongation and ventricular arrhythmias. Ann. New York Acad. Sci., 664 (Suppl.), 1, 1993.
23. Vozej S., Uematsu T., Guenter T.W., Follath F. Kinetics and electrocardiographic changes after oral 3-hydroxy-quinidine in healthy subjects. Clin. Pharmacol. Ther., 37, 575, 1985.